Table of Contents
DAYTON, N.J. — Aurobindo Pharma Ltd. has received final approval from the Food and Drug Administration for rivastigmine tartrate capsules, a dementia medication, in dosages of 1.5 mg, 3 mg, 4.5 mg and 6 mg.
Aurobindo said Monday that its rivastigmine tartrate product (1.5 mg, 3 mg, 4.5 mg and 6 mg) is a generic equivalent of Exelon capsules from Novartis.
Rivastigmine tartrate capsules are indicated for the treatment of mild to moderate dementia from Alzheimer’s disease and mild to moderate dementia associated with Parkinson’s disease.
The product had total U.S. sales of $26.2 million for the 12 months ended in February, according to IMS Health data reported by Aurobindo.
